Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EPS (Weighted Average and Diluted) (2023 - 2025)

Camp4 Therapeutics' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.86 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 101.31% year-over-year to -$0.86; the TTM value through Dec 2025 reached -$2.65, up 76.53%, while the annual FY2025 figure was -$2.65, 76.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.86 at Camp4 Therapeutics, down from -$0.55 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $65.46 in Q4 2024 and bottomed at -$34.33 in Q4 2023.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$12.52 (2024), against an average of -$7.75.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 290.69% in 2024 before it tumbled 101.31% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$34.33 in 2023, then soared by 290.69% to $65.46 in 2024, then plummeted by 101.31% to -$0.86 in 2025.
  • Per Business Quant, the three most recent readings for CAMP's EPS (Weighted Average and Diluted) are -$0.86 (Q4 2025), -$0.55 (Q3 2025), and -$0.62 (Q2 2025).